Lichtenegger F.S.,Ludwig Maximilians University of Munich |
Lichtenegger F.S.,Clinical Cooperation Group Immunotherapy at the Helmholtz Institute Munich |
Krupka C.,Ludwig Maximilians University of Munich |
Krupka C.,Clinical Cooperation Group Immunotherapy at the Helmholtz Institute Munich |
And 4 more authors.
Seminars in Hematology | Year: 2015
Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts. The patients medically fit for intensive induction therapy have a high complete remission rate but the majority suffers from relapse due to chemo-refractory leukemic cells. Allogeneic stem cell transplantation as post-remission therapy can significantly reduce the likelihood of relapse, but it is associated with a high rate of morbidity and mortality. Novel therapeutic concepts are therefore urgently sought after. During recent years, the focus has shifted towards the development of novel immunotherapeutic strategies. Some of the most promising are drug-conjugated monoclonal antibodies, T-cell engaging antibody constructs, adoptive transfer with chimeric antigen receptor (CAR) T cells, and dendritic cell vaccination. Here, we review recent progress in these four fields and speculate about the optimal time points during the course of AML treatment for their application. © 2015 Elsevier Inc. Source